Literature DB >> 21748131

Lipids-risk categories in omani type 2 diabetics: impact of the national cholesterol educational program.

Ali I Al-Bahrani1, Riad Bayoumi, Said A Al-Yahyaee.   

Abstract

OBJECTIVE: To evaluate the impact of the National Cholesterol Educational Program Adult Treatment Panel III (ATP III) and the Framingham Offspring Study on Omani diabetic subjects.
METHODS: 221 subjects with type 2 diabetes (86 females and 135 males) and 156 non-diabetic subjects (70 females and 86 males) aged 30-70 years attending Sultan Qaboos University Hospital between 1999-2002 were recruited. Lipid profile, glucose, %HbA(1c), apoproteinA-1 and apoproteinB were measured. Low density lipoprotein was calculated using the Friedwald formula. ATP-III and Framingham Offspring Study guidelines were used to classify lipid parameters into coronary heart disease-risk categories.
RESULTS: Diabetic compared to non-diabetic subjects had significantly higher triglycerides of >1.7 mmol/L (p=0.01) and lower low density lipoprotein cholesterol of >4.2 mmol/L (p=0.012) and, in female subjects only, lower high density lipoprotein cholesterol of <1.15 mmo/L for (p<0.0001). In addition, 57% of diabetic subjects had abnormal aplipoproteinB of >1.2 g/L compared to 49% of non-diabetic subjects. Combined raised levels of triglycerides, apolipoproteinB and low levels of high density lipoprotein were found in 42% of diabetic compared to 26% of the non-diabetic subjects (p=0.05). Diabetic subjects had significantly higher (p=0.008) NCEP risk-score for coronary artery disease, however, only 34% conformed to a NCEP 10-year-risk score of >10%.
CONCLUSION: A substantial proportion of the Omani diabetic subjects were dyslipidaemic according to the ATP III guidelines. This study recommends the implementation of a lower cut-off threshold for starting lipid-modifying agents for Omani diabetics when using the 10-year Framingham Risk Scoring equation.

Entities:  

Keywords:  Lipids; Lipoproteins; NCEP risk score; Oman; diabetes mellitus

Year:  2006        PMID: 21748131      PMCID: PMC3074919     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  17 in total

1.  Calculation of coronary risk in Type II diabetes.

Authors:  P Durrington
Journal:  Clin Sci (Lond)       Date:  2001-12       Impact factor: 6.124

2.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

3.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

4.  Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry.

Authors:  M Haim; M Benderly; D Brunner; S Behar; E Graff; H Reicher-Reiss; U Goldbourt
Journal:  Circulation       Date:  1999-08-03       Impact factor: 29.690

5.  Increasing prevalence of diabetes mellitus in Oman.

Authors:  J A Al-Lawati; A M Al Riyami; A J Mohammed; P Jousilahti
Journal:  Diabet Med       Date:  2002-11       Impact factor: 4.359

6.  High prevalence of diabetes mellitus and impaired glucose tolerance in the Sultanate of Oman: results of the 1991 national survey.

Authors:  M G Asfour; A Lambourne; A Soliman; S Al-Behlani; D Al-Asfoor; A Bold; H Mahtab; H King
Journal:  Diabet Med       Date:  1995-12       Impact factor: 4.359

7.  Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials.

Authors:  I Jungner; S M Marcovina; G Walldius; I Holme; W Kolar; E Steiner
Journal:  Clin Chem       Date:  1998-08       Impact factor: 8.327

8.  Prevalence of the metabolic syndrome among Omani adults.

Authors:  Jawad A Al-Lawati; Ali J Mohammed; Halima Q Al-Hinai; Pekka Jousilahti
Journal:  Diabetes Care       Date:  2003-06       Impact factor: 19.112

9.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleigh; Richard Peto
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

10.  Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study.

Authors:  J H Contois; J R McNamara; C J Lammi-Keefe; P W Wilson; T Massov; E J Schaefer
Journal:  Clin Chem       Date:  1996-04       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.